Used MIMS Philippines - Drug Information, Disease, News for Android?


MIMS Philippines - Drug Information, Disease, News Analysis

AI Assisted Content ·

Not written by CNET Staff.

MIMS Philippines - Drug Information, Disease, News is an educational software application designed for Android users. This free app provides access to a wide array of drug information, including detailed descriptions, indications, dosages, and potential side effects. It also features a database of diseases, allowing users to search for conditions and obtain relevant medical information. The app is tailored to healthcare professionals and students, enhancing their knowledge and reference capabilities in clinical settings.

Top Recommended Alternative

In addition to drug and disease information, MIMS Philippines offers the latest health news, keeping users updated on current medical trends and research. The app's user-friendly interface facilitates easy navigation, making it simple to find specific information quickly. With its extensive resources, the application serves as a valuable tool for anyone interested in health and fitness, particularly those involved in the medical field.

Enlarged image for MIMS Philippines - Drug I…
MIMS Philippines - Drug Information, Disease, News 0/4

Used MIMS Philippines - Drug Information, Disease, News for Android?


Explore More


Full Specifications

GENERAL
Release
Latest update
Version
2.0.12
OPERATING SYSTEMS
Platform
Android
Operating System
Android 9.0
POPULARITY
Total Downloads
630
Downloads Last Week
0

Report Software

Program available in other languages


Last Updated


Developer’s Description

By MIMS
For over 50 years, MIMS has provided trusted and relevant clinical information for over two million healthcare professionals in Asia.

Download.com
Your review for MIMS Philippines - Drug Information, Disease, News
Download.com

AI Assisted Content Disclosure

Content created and reviewed by Softonic with information obtained from MIMS, using AI.

CNET's editorial team was not involved in the creation of this content. Opinions, analysis and reviews were not provided by CNET.